603127 昭衍新药
已收盘 04-21 15:00:00
资讯
新帖
简况
昭衍新药上周获融资净买入1264.42万元,居两市第232位
金融界 · 04-20 23:54
昭衍新药上周获融资净买入1264.42万元,居两市第232位
动物实验需求或将减少 “猴茅”昭衍新药受冲击
中国经营网 · 04-18
动物实验需求或将减少 “猴茅”昭衍新药受冲击
易方达基金管理有限公司减持昭衍新药(06127)306.43万股 每股作价约9.92港元
智通财经 · 04-17
易方达基金管理有限公司减持昭衍新药(06127)306.43万股 每股作价约9.92港元
A股CRO概念震荡反弹,双成药业6天5板,诺思格涨超10%,河化股份、新天地、宣泰医药、昭衍新药等跟涨。
美港电讯 · 04-17
A股CRO概念震荡反弹,双成药业6天5板,诺思格涨超10%,河化股份、新天地、宣泰医药、昭衍新药等跟涨。
昭衍新药:公司不存在应披露而未披露的信息
证券之星 · 04-16
昭衍新药:公司不存在应披露而未披露的信息
昭衍新药04月16日遭主力抛售3029万元
市场透视 · 04-16
昭衍新药04月16日遭主力抛售3029万元
FDA新政策下,昭衍新药的猴子白囤了?
虎嗅网 · 04-15
FDA新政策下,昭衍新药的猴子白囤了?
“猴茅”神话终结?昭衍新药净利从增九成到降八成,只隔一年
投资时报 · 04-15
“猴茅”神话终结?昭衍新药净利从增九成到降八成,只隔一年
昭衍新药04月15日主力净流出2285万元 散户资金买入
市场透视 · 04-15
昭衍新药04月15日主力净流出2285万元 散户资金买入
昭衍新药透过中信证券认购金融产品 投资总额达4亿元
新浪港股 · 04-15
昭衍新药透过中信证券认购金融产品 投资总额达4亿元
昭衍新药(06127)透过中信证券认购金融产品 投资总额达4亿元
智通财经 · 04-14
昭衍新药(06127)透过中信证券认购金融产品 投资总额达4亿元
易方达基金管理有限公司增持昭衍新药(06127)16.28万股 每股作价约13.89港元
智通财经 · 03-11
易方达基金管理有限公司增持昭衍新药(06127)16.28万股 每股作价约13.89港元
昭衍新药03月11日主力净流入837万元 散户资金抛售
市场透视 · 03-11
昭衍新药03月11日主力净流入837万元 散户资金抛售
港股异动 | 昭衍新药(06127)尾盘涨超7% AI制药潜力释放 有望赋能公司药物非临床研究
智通财经 · 03-10
港股异动 | 昭衍新药(06127)尾盘涨超7% AI制药潜力释放 有望赋能公司药物非临床研究
AI赋能医疗服务企业提质增效,多场景应用覆盖患者全生命诊疗周期
环球网 · 03-07
AI赋能医疗服务企业提质增效,多场景应用覆盖患者全生命诊疗周期
昭衍新药03月07日主力净流出745万元 散户资金买入
市场透视 · 03-07
昭衍新药03月07日主力净流出745万元 散户资金买入
医疗健康行业2024年专利分析白皮书
知识产权出版社 · 03-06
医疗健康行业2024年专利分析白皮书
加载失败,点击重试
公司概况
公司名称:
北京昭衍新药研究中心股份有限公司
所属行业:
研究和试验发展
上市日期:
2017-08-25
主营业务:
北京昭衍新药研究中心股份有限公司的主营业务是从事以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。
发行价格:
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":15.61,"timestamp":1745218800000,"preClose":15.52,"halted":0,"volume":17604648,"delay":0,"changeRate":0.0058,"floatShares":630000000,"shares":749000000,"eps":-0.3321,"marketStatus":"已收盘","change":0.09,"latestTime":"04-21 15:00:00","open":15.49,"high":15.65,"low":15.26,"amount":273000000,"amplitude":0.0251,"askPrice":15.61,"askSize":975,"bidPrice":15.6,"bidSize":902,"shortable":0,"etf":0,"ttmEps":-0.3321,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.52,"symbolType":"stock","openAndCloseTimeList":[[1745199000000,1745206200000],[1745211600000,1745218800000]],"highLimit":17.07,"lowLimit":13.97,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749477334,"isCdr":false,"pbRate":1.45,"roa":"--","roe":"0.91%","epsLYR":0.1,"committee":0.306164,"marketValue":11699000000,"turnoverRate":0.0279,"status":0,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":9.79,"timestamp":1744877289036,"preClose":9.77,"halted":0,"volume":2754504,"delay":0,"premium":"-41.06"},"floatMarketCap":9842000000},"requestUrl":"/m/hq/s/603127/tweets","defaultTab":"tweets","newsList":[{"id":"2529707897","title":"昭衍新药上周获融资净买入1264.42万元,居两市第232位","url":"https://stock-news.laohu8.com/highlight/detail?id=2529707897","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529707897?lang=zh_cn&edition=full","pubTime":"2025-04-21 07:54","pubTimestamp":1745193244,"startTime":"0","endTime":"0","summary":"4月21日,沪深两融数据显示,昭衍新药上周累计获融资净买入额1264.42万元,居两市第232位,上周融资买入额1.42亿元,偿还额1.30亿元。资金流方面,昭衍新药近5日主力资金流出542.53万元,区间跌幅0.28%;近10日主力资金流出2.83亿元,区间跌幅6.73%。通过天眼查大数据分析,北京昭衍新药研究中心股份有限公司共对外投资了20家企业,参与招投标项目42次,知识产权方面有商标信息67条,专利信息55条,此外企业还拥有行政许可43个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/21075449696581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK1141","BK0216","06127","603127"],"gpt_icon":0},{"id":"2528192890","title":"动物实验需求或将减少 “猴茅”昭衍新药受冲击","url":"https://stock-news.laohu8.com/highlight/detail?id=2528192890","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528192890?lang=zh_cn&edition=full","pubTime":"2025-04-19 03:48","pubTimestamp":1745005680,"startTime":"0","endTime":"0","summary":"近期,FDA 官方网站宣布计划逐步取消单抗和其他药物的动物实验要求。动物实验或将被替代根据公告,FDA将转而采用一系列新兴的替代技术,包括基于AI毒性预测模型、细胞系以及实验室环境下的类器官毒性测试等。“猴周期”下行实际上,昭衍新药的命运与实验猴价格深度绑定。当FDA新政与国内药监机构类器官技术推广形成合围,其核心业务面临需求减少的风险。昭衍新药方面如是说。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041904092894da6fdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041904092894da6fdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","06127","BK1576","603127"],"gpt_icon":0},{"id":"2528966796","title":"易方达基金管理有限公司减持昭衍新药(06127)306.43万股 每股作价约9.92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528966796","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528966796?lang=zh_cn&edition=full","pubTime":"2025-04-17 17:46","pubTimestamp":1744883202,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,4月11日,易方达基金管理有限公司减持昭衍新药(06127)306.43万股,每股作价为9.921港元,总金额约为3040.09万港元。减持后最新持股数目为620.24万股,持股比例为5.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK1141","603127","BK1576","BK0216"],"gpt_icon":0},{"id":"2528780451","title":"A股CRO概念震荡反弹,双成药业6天5板,诺思格涨超10%,河化股份、新天地、宣泰医药、昭衍新药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528780451","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528780451?lang=zh_cn&edition=full","pubTime":"2025-04-17 10:16","pubTimestamp":1744856163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["301277","BK0077","06127","BK0004","002693","399300","603127","BK0071","BK0216","BK0239","BK1141","BK1576","BK0066","301333","000953","BK0010","688247","159982"],"gpt_icon":0},{"id":"2527256329","title":"昭衍新药:公司不存在应披露而未披露的信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2527256329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527256329?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:34","pubTimestamp":1744788883,"startTime":"0","endTime":"0","summary":"证券之星消息,昭衍新药(603127)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好!今天贵司股价无故跌停,盘后显示机构大幅出逃,请问贵司是否有应披露而未披露信息?贵司一季报业绩是否提前被机构提前知晓,机构选择借多年前利空消息抢跑,导致股价大跌,谢谢昭衍新药回复:您好!公司不存在应披露而未披露的信息,可查阅公司于4月12日披露的相关公告,谢谢。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041600018983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127","BK1141","BK1576","BK0216"],"gpt_icon":0},{"id":"2527426105","title":"昭衍新药04月16日遭主力抛售3029万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527426105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527426105?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:22","pubTimestamp":1744788152,"startTime":"0","endTime":"0","summary":"04月16日, 昭衍新药股价跌4.51%,报收15.44元,成交金额3.68亿元,换手率3.75%,振幅4.95%,量比0.70。昭衍新药今日主力资金净流出3029万元,上一交易日主力净流出2285万元。该股近5个交易日下跌9.55%,主力资金累计净流出2.86亿元;近20日主力资金累计净流出3.58亿元,其中净流出天数为13日。|04月16日主力加仓幅度排名||#|股票简称|主力净额占比|#|N肯特|19.77%|#|亚联机械|7.56%|#|健尔康|6.15%|#|...|...|#4735|昭衍新药|-0.31%|昭衍新药所在的医疗服务行业,今日主力净流出4.31亿元,行业排名31/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416172036a6bc5eb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416172036a6bc5eb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603127","BK0216"],"gpt_icon":0},{"id":"2527289122","title":"FDA新政策下,昭衍新药的猴子白囤了?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527289122","media":"虎嗅网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527289122?lang=zh_cn&edition=full","pubTime":"2025-04-16 00:00","pubTimestamp":1744732800,"startTime":"0","endTime":"0","summary":"这意味着,FDA此次并非是“拍脑门”推出的政策,或许有一定的依据。其中,动物试验占到70%左右,这部分是在未来会受到上述FDA政策直接冲击的业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504161105399739590d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504161105399739590d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","06127","603127"],"gpt_icon":0},{"id":"2527545574","title":"“猴茅”神话终结?昭衍新药净利从增九成到降八成,只隔一年","url":"https://stock-news.laohu8.com/highlight/detail?id=2527545574","media":"投资时报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527545574?lang=zh_cn&edition=full","pubTime":"2025-04-15 15:22","pubTimestamp":1744701763,"startTime":"0","endTime":"0","summary":"随着猴子涨价,昭衍新药业绩一飞冲天,2022年公司营收同比增长49.54%至22.68亿元,归母净利润大幅增长92.71%至10.74亿元。AI替代不再是一个概念业绩下滑是昭衍新药股价下跌的原因之一,但给4月11日的公司股价“最后一击”的还是FDA发布的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504151523009738492d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504151523009738492d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","06127","603127"],"gpt_icon":0},{"id":"2527681804","title":"昭衍新药04月15日主力净流出2285万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527681804","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527681804?lang=zh_cn&edition=full","pubTime":"2025-04-15 15:21","pubTimestamp":1744701672,"startTime":"0","endTime":"0","summary":"04月15日, 昭衍新药股价跌2.41%,报收16.17元,成交金额3.66亿元,换手率3.57%,振幅3.86%,量比0.66。昭衍新药今日主力资金净流出2285万元,上一交易日主力净流入2578万元。该股近5个交易日下跌6.32%,主力资金累计净流出2.53亿元;近20日主力资金累计净流出2.97亿元,其中净流出天数为12日。|04月15日主力加仓幅度排名||#|股票简称|主力净额占比|#|N信凯科技|23.75%|#|三态股份|8.94%|#|新亚电缆|8.44%|#|...|...|#4654|昭衍新药|-0.22%|昭衍新药所在的医疗服务行业,今日主力净流入5689万元,行业排名22/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415163028a45970af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415163028a45970af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603127","BK0216"],"gpt_icon":0},{"id":"2527174976","title":"昭衍新药透过中信证券认购金融产品 投资总额达4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527174976","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527174976?lang=zh_cn&edition=full","pubTime":"2025-04-15 09:00","pubTimestamp":1744678800,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 昭衍新药(06127)发布公告,于2025年4月14日(交易时间后),集团成员公司刚透过中信证券及其附属公司认购且于本公告日期仍未到期的该等中信证券金融产品合计投资总额分别为人民币4亿元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-15/doc-inetfaiy8621972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","LU2289578879.USD","LU1997245094.SGD","BK0183","06030","LU0405327494.USD","LU1794554557.SGD","BK1521","159940","LU1328615791.USD","06127","LU0405327148.USD","BK1576","LU2495084118.USD","LU1720050803.USD","LU2148510915.USD","LU1997244956.HKD","600030","BK1516","BK1147","BK0012","BK0028","BK1141","LU1997245177.USD","BK0216","BK1564","BK0188","BK0196","LU1064130708.USD","LU1064131003.USD","BK0276"],"gpt_icon":0},{"id":"2527658164","title":"昭衍新药(06127)透过中信证券认购金融产品 投资总额达4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527658164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527658164?lang=zh_cn&edition=full","pubTime":"2025-04-14 21:30","pubTimestamp":1744637416,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昭衍新药(06127)发布公告,于2025年4月14日(交易时间后),集团成员公司刚透过中信证券及其附属公司认购且于本公告日期仍未到期的该等中信证券金融产品合计投资总额分别为人民币4亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1576","BK0028","06030","LU1997245094.SGD","LU0405327494.USD","BK0216","LU1794554557.SGD","06127","BK1516","LU1328615791.USD","BK0012","BK1141","LU1997244956.HKD","LU1720050803.USD","BK1147","159940","LU2148510915.USD","600030","LU2289578879.USD","BK0183","LU1064131003.USD","BK1564","LU0405327148.USD","BK1521","BK0188","LU2495084118.USD","603127","BK0276","LU1064130708.USD","LU1997245177.USD"],"gpt_icon":0},{"id":"2518711722","title":"易方达基金管理有限公司增持昭衍新药(06127)16.28万股 每股作价约13.89港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518711722","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518711722?lang=zh_cn&edition=full","pubTime":"2025-03-11 18:32","pubTimestamp":1741689138,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,3月5日,易方达基金管理有限公司增持昭衍新药(06127)16.28万股,每股作价为13.8914港元,总金额约为226.15万港元。增持后最新持股数目为720.75万股,持股比例为6.06%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","603127","BK0216","06127","BK1576"],"gpt_icon":0},{"id":"2518903247","title":"昭衍新药03月11日主力净流入837万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2518903247","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518903247?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:20","pubTimestamp":1741677655,"startTime":"0","endTime":"0","summary":"03月11日, 昭衍新药股价涨2.25%,报收21.77元,成交金额2.26亿元,换手率1.67%,振幅4.32%,量比1.25。昭衍新药今日主力资金净流入837万元,上一交易日主力净流出199万元。该股近5个交易日上涨4.06%,主力资金累计净流出1030万元;近20日主力资金累计净流出7332万元,其中净流出天数为14日。该股主力净额占比0.06%,A股市场排名1163/5397,高于行业平均值。净流出前三个股分别为迪安诊断、药明康德、美年健康。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311162034a1d48a05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311162034a1d48a05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603127","BK0216"],"gpt_icon":0},{"id":"2518295302","title":"港股异动 | 昭衍新药(06127)尾盘涨超7% AI制药潜力释放 有望赋能公司药物非临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2518295302","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518295302?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:10","pubTimestamp":1741590618,"startTime":"0","endTime":"0","summary":"海通证券指出,在药物非临床研究领域,昭衍新药引进了数字病理辅助分析系统,该系统实现了包括实验动物种属多脏器类别的AI辅助诊断、数字切片智能质控、AI模型自主训练等场景的应用。AI辅助诊断的应用使病理诊断更快、更精准。采用AI分析数据后,人效比在部分环节实现进一步提高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","01477","BK1574","BK0216","603127","BK1141","BK1191","06127"],"gpt_icon":0},{"id":"2517433243","title":"AI赋能医疗服务企业提质增效,多场景应用覆盖患者全生命诊疗周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2517433243","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517433243?lang=zh_cn&edition=full","pubTime":"2025-03-07 15:32","pubTimestamp":1741332736,"startTime":"0","endTime":"0","summary":"根据国泰君安研报,DeepSeek的突破性技术显著加速AI在医疗行业的应用进程,多场景应用覆盖患者全生命诊疗周期,赋能医疗服务企业提升服务效率和质量,实现降本增效。AI医生能够加速青年医生培养,提升优质医疗资源供给。此外,AI智能助手助力医生在预问诊、电子病历生成和质量控制等方面提升效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307153301989f8907&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307153301989f8907&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","688265","BK0284","600763","688710","BK0239","603127","688238","BK0077","688222","688315","688131","BK0139","688046","BK0188","603259","688073","BK0132","688621","688202","603882","603456","600721","600568"],"gpt_icon":0},{"id":"2517105423","title":"昭衍新药03月07日主力净流出745万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2517105423","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517105423?lang=zh_cn&edition=full","pubTime":"2025-03-07 15:23","pubTimestamp":1741332204,"startTime":"0","endTime":"0","summary":"03月07日, 昭衍新药股价跌2.22%,报收21.12元,成交金额1.49亿元,换手率1.11%,振幅2.59%,量比0.61。昭衍新药今日主力资金净流出745万元,上一交易日主力净流入360万元。该股近5个交易日上涨1.73%,主力资金累计净流出2932万元;近20日主力资金累计净流出8642万元,其中净流出天数为15日。该股主力净额占比0.06%,A股市场排名3108/5685,高于行业平均值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307165238abecc19f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307165238abecc19f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","603127"],"gpt_icon":0},{"id":"2517046438","title":"医疗健康行业2024年专利分析白皮书","url":"https://stock-news.laohu8.com/highlight/detail?id=2517046438","media":"知识产权出版社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517046438?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:00","pubTimestamp":1741276800,"startTime":"0","endTime":"0","summary":"本报告从医疗健康行业全球专利竞争态势、支撑技术和业务应用场景等维度进行分析,以期全面了解医疗健康行业专利竞争发展现状。中国医疗健康行业的专利申请数量已超过18.7 万件,占全球总量的51.7%,远超过其他国家。平安集团以4176 件医疗健康行业专利申请位居第一位,飞利浦以微弱差距位居第二,两家企业专利申请量远超其他专利权人,专利优势突出,技术创新实力明显超过其他主体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307200225a26426e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307200225a26426e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688238","688617","603658","600085","600521","688710","BK0196","LU0405327148.USD","LU1328615791.USD","LU1969619763.USD","LU0405327494.USD","603087","600763","600721","600079","688578","603127","688073","688046","688621","600276","LU2148510915.USD","600436","688202","688222","600566","BK0239","BK0012","LU1064130708.USD","600380","LU2328871848.SGD","600161","600332","600568","600196","LU2488822045.USD","603882","688271","BK0188","BK0060","603456","BK0028","603259","688265","688278","LU1064131003.USD","159760","688131","688315","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1745277772761,"stockEarnings":[{"period":"1week","weight":-0.0579},{"period":"1month","weight":-0.2584},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.1008},{"period":"1year","weight":-0.059},{"period":"ytd","weight":-0.0613}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.0151},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.0738},{"period":"ytd","weight":-0.018}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74947万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是从事以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}